Litschgi M S, Da Rugna D, Mladenović D, Grcić R
Fortschr Med. 1980 Nov 6;98(41):1624-7.
This is the report on a multi-centre study of the treatment of 444 women with trichomoniasis vaginalis using Solcotrichovac, a vaccine containing at least 7 x 10(9) inactivated microorganisms of various strains of lactobacillus acidophilus in each 0.5 ml dose. One year after the first vaccination 427 of the patients (96.2%) were followed up, and 92.5% of them were found to be cured of clinical symptoms; the remaining 7.5% must be considered as not cured, as either the slide or the culture was positive. We are convinced by these results that vaccination with Solcotrichovac represents an enhancement of therapeutic opportunities for the treatment of trichomoniasis vaginalis.